AstraZeneca (AZN) and Chi-Med Amend Agreement Regarding Savolitinib
AstraZeneca (NYSE: AZN) and Hutchison China MediTech Limited (NASDAQ: HCM), also known as Chi-Med, have announced the amending of a 2011 global licensing and commercialization agreement regarding savolitinib in order to increase its global development. In addition to increasing the global development, Chi-Med will be able to have more involvement in the project. With this in mind, savolitinib’s worldwide expansion will help with a number of Met-driven tumors, such as specific types of lung cancer, colorectal, gastric and kidney cancers. With the phase II open-label global PRCC results from savolitinib recently finished and being presented at a scientific meeting, Chi-Med…







